Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study

Sorafenib is an oral multikinase inhibitor that has been approved to treat advanced hepatocellular carcinoma (HCC), though it is unclear how much benefit advanced HCC patients with progressive disease (PD) derive from sorafenib treatment. This study aimed to assess survival risk factors and evaluate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Nakano, Masahito, Tanaka, Masatoshi, Kuromatsu, Ryoko, Nagamatsu, Hiroaki, Satani, Manabu, Niizeki, Takashi, Okamura, Shusuke, Iwamoto, Hideki, Shimose, Shigeo, Shirono, Tomotake, Noda, Yu, Koga, Hironori, Torimura, Takuji
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Clinical Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5325452/
https://ncbi.nlm.nih.gov/pubmed/27462865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10794
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados